StockNews.AI
RAPP
StockNews.AI
2 hrs

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

1. Rapport Therapeutics will participate in a virtual investor conference on September 17, 2025. 2. The company focuses on precision medicines for neurological and psychiatric disorders. 3. RAP-219 targets specific brain regions for effective treatment of focal onset seizures, bipolar mania. 4. Additional programs focus on chronic pain and hearing disorders.

3m saved
Insight
Article

FAQ

Why Bullish?

Participation in investor conferences often boosts visibility and credibility. Historical cases show positive market responses to biotech presentations at such events.

How important is it?

The announcement connects directly to investor engagement and potential price movement, crucial for RAPP's market perception.

Why Short Term?

Market reactions are likely immediate, driven by investor sentiment following the presentation. Previous similar events have shown quick price corrections post-announcements.

Related Companies

BIIBVRTXSGEN
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor conference. TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (virtual) – fireside chat on Wednesday, September 17, 2025, at 11:20 am ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.rapportrx.com. About Rapport TherapeuticsRapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders. ContactJulie DiCarloHead of Communications & IRRapport Therapeuticsjdicarlo@rapportrx.com

Related News